Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key factors driving the growth of the human microbiome market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.

The human microbiome market has been segmented based on product, type, application, disease, and region.

“By application, the therapeutics segment accounted for the largest share of the human microbiome market”

Based on application, the human microbiome market is categorized into therapeutics, and diagnostics. The therapeutics segment dominated the market in 2023, owing to the increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.

“By disease, infectious diseases segment accounted for the largest share in the human microbiome market”

Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. In 2023, the infectious diseases segment accounted for a larger share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the role of the microbiome in human health and the development of advanced sequencing and bioinformatics techniques are paving the way for the discovery and characterization of novel microbiome-based therapeutics for the prevention and treatment of infectious diseases.

“North America: the largest share of the human microbiome market”

North America accounted for the largest share of the human microbiome market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in microbiome research. The presence of top academic institutions, research hospitals, and private companies in North America with dedicated microbiome research programs and expertise has contributed to the growth of the human microbiome market.

“Asia Pacific: The fastest-growing region in the human microbiome market.”

The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific human microbiome market is the region's large and rapidly aging population.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 60% and Demand Side 40%

By Designation: Executives - 40%, Research Scientists- 30%, and Managers - 30%

By Country: North America- 22%, Europe- 42%, Asia Pacific- 11%, Rest of the World- 25%

Prominent Players

Seres Therapeutics, Inc. (US)

Enterome (France)

4D pharma plc (UK)

International Flavors & Fragrances Inc. (US)

OptiBiotix Health Plc (UK)

Ferring Pharmaceuticals (Switzerland)

Synlogic, Inc. (US)

Second Genome, Inc. (US)

Vedanta Biosciences, Inc. (US)

YSOPIA Bioscience (France)

FlightPath Biosciences, Inc. (US)

Finch Therapeutics Group, Inc. (US)

AOBiome Therapeutics (US)

BioGaia (Sweden)

Quantbiome, Inc. (dba Ombre) (US)

Viome Life Sciences, Inc. (US)

BIOHM Health (US)

DayTwo (US)

Atlas Biomed (UK)

Bione Ventures Private Limited (India)

Luxia Scientific (France)

Metabiomics (US)

Sun Genomics (US)

Seed Health (US)

Gnubiotics Sciences (Switzerland)

Research Coverage:

This report provides a detailed picture of the human microbiome market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (drugs, diagnostics tests, probiotics, prebiotics, and other products), application (therapeutic, and diagnostics), disease (infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, and other diseases), type (Bacterial consortia transplantation (BCT)/ fecal microbiota transplantation(FMT), peptides, live biotherapeutic products, and other types), and region (North America, Europe, Asia Pacific, and Rest of the World). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall human microbiome market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers”

Analysis of key drivers (collaborative efforts between microbiome industry and academia for microbiome research, surging demand for personalized medicine, and rising awareness about importance of human microbiome), restraints (adverse impact of complex regulatory policies on commercialization of microbiomes), opportunities (increased collaboration of key players and small innovative companies collaborating to work on new microbiome technologies, and advancements in sequencing and bioinformatics), and challenges (low patient adoption rate of microbiome-based therapies, and complexities involved in development of microbiome therapies) influencing the growth of the human microbiome market.

Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the human microbiome market.

Market Development: Comprehensive information about lucrative markets- the report analyses the human microbiome market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human microbiome market.

Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK) among others in the human microbiome market strategies. The report also helps stakeholders understand the pulse of the animal research model market and provides them information on key market drivers, restraints, challenges and opportunities.